Objective:
To evaluate the efficacy of NCX 470 in lowering intraocular pressure (IOP) compared to latanoprost in patients with open-angle glaucoma and ocular hypertension.
Key Findings:
- NCX 470 achieved a statistically significant greater proportion of eyes with IOP ≤18 mmHg compared to latanoprost, but did not meet the prespecified secondary efficacy endpoint of statistical superiority over latanoprost.
- NCX 470 was numerically superior at all time points for IOP change.
Interpretation:
NCX 470 shows promise as a treatment option for lowering IOP in glaucoma patients, particularly in comparison to the standard treatment, latanoprost.
Limitations:
- The Mont Blanc trial did not meet all prespecified efficacy endpoints, which may affect the interpretation of the results.
- Results are based on post hoc analysis, which may limit the robustness of conclusions.
Conclusion:
NCX 470 is currently under further evaluation in pivotal trials, including the Denali and Whistler trials, with potential for FDA filing in 2026.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.